Tarafenacin

Drug Profile

Tarafenacin

Alternative Names: SVT-40776

Latest Information Update: 30 Jul 2015

Price : $50

At a glance

  • Originator SALVAT
  • Developer Kwang Dong Pharmaceutical; SALVAT
  • Class Antispasmodics; Quinuclidines
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Overactive bladder

Highest Development Phases

  • No development reported Overactive bladder

Most Recent Events

  • 30 Jul 2015 No recent reports on development identified - Phase-II for Overactive bladder in USA, Australia, Czech Republic, Germany, Hungary, Netherlands, New Zealand, Russia, South Africa, South Korea and Spain (PO)
  • 09 Apr 2013 Efficacy and adverse events data from a phase IIb trial in Overactive bladder in South Korea released by SALVAT and Kwang Dong
  • 09 Apr 2013 SALVAT and Kwang Dong complete a phase IIb trial in Overactive bladder in South Korea (NCT01458197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top